Effects of Carnitine on Valproic Acid Pharmacokinetics in Rats

被引:4
作者
Katayama, Hirokazu [1 ]
Mizukami, Kohki [1 ]
Yasuda, Manami [1 ]
Hatae, Tomomi [1 ]
机构
[1] Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Fukuyama, Hiroshima, Japan
关键词
valproic acid; carnitine; renal clearance; beta-oxidation; pharmacokinetics; metabolism; metabolite kinetics; renal excretion; drug interaction; glucuronide; SHORT-TERM TREATMENT; PIVALIC ACID; ANTIEPILEPTIC DRUGS; EPILEPTIC PATIENTS; METABOLISM; PLASMA; THERAPY; PRODRUG;
D O I
10.1016/j.xphs.2016.06.024
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The long-term administration of valproic acid (VPA) may decrease the plasma concentrations of L-carnitine in epileptic patients. L-Carnitine is essential for the beta-oxidation of fatty acids. The aim of this study is to determine whether endogenous L-carnitine affects the pharmacokinetics of VPA in L-carnitine-deficient (CD) rats. An L-carnitine deficiency was induced in rats using sodium pivalate. The pharmacokinetics of VPA were examined following its intravenous or oral administration to rats. The plasma and urine concentrations of VPA and its metabolites were determined using gas chromatography-mass spectrometry methods. Plasma VPA concentrations were slightly higher in CD rats than in control rats, whereas no significant differences were observed in the area under the curve or mean residence times of VPA between the 2 groups. After i.v. administration, the slope of the elimination phase (k) was significantly higher in CD rats than in control rats (p < 0.01). Some of the b-oxidation metabolites of VPA in plasma and urine decreased, while the glucuronide metabolites of VPA in urine increased complementarily in CD rats. Based on these results, it was concluded that hypocarnitinemia could affect the pharmacokinetics of VPA. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:3199 / 3204
页数:6
相关论文
共 27 条
[1]   THE EFFECT OF ASPIRIN ON VALPROIC ACID METABOLISM [J].
ABBOTT, FS ;
KASSAM, J ;
ORR, JM ;
FARRELL, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (01) :94-100
[2]  
Bauer LA, 1989, PHARMACOTHERAPY PATH, V4
[3]   VALPROIC ACID DOSAGE AND PLASMA-PROTEIN BINDING AND CLEARANCE [J].
BOWDLE, TA ;
PATEL, IH ;
LEVY, RH ;
WILENSKY, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (04) :486-492
[4]   Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil [J].
Brass, EP ;
Mayer, MD ;
Mulford, DJ ;
Stickler, TK ;
Hoppel, CL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :338-347
[5]   PHARMACOKINETICS OF VALPROIC ACID IN YOUNG AND ELDERLY SUBJECTS [J].
BRYSON, SM ;
VERMA, N ;
SCOTT, PJW ;
RUBIN, PC .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (01) :104-105
[6]   Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin [J].
De Turck, BJG ;
Diltoer, MW ;
Cornelis, PJWW ;
Maes, V ;
Spapen, HDM ;
Camu, F ;
Huyghens, LP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :563-564
[7]  
DICKINSON RG, 1986, DRUG METAB DISPOS, V14, P255
[8]  
Dickinson RG, 1979, PHARM EXP THER, V211, P583
[9]  
Fujii Ryochi, 1993, Japanese Journal of Antibiotics, V46, P926
[10]   ASPECTS OF THE METABOLISM OF VALPROIC ACID [J].
GRANNEMAN, GR ;
WANG, SI ;
MACHINIST, JM ;
KESTERSON, JW .
XENOBIOTICA, 1984, 14 (05) :375-387